{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:40:05Z","timestamp":1748875205792,"version":"3.41.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40487-025-00340-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:44:35Z","timestamp":1747223075000},"page":"465-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors"],"prefix":"10.1007","volume":"13","author":[{"given":"Daphne W. M.","family":"Voogd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-9449","authenticated-orcid":false,"given":"Merel J. J.","family":"Lucassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud","family":"van der Noll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybrand W. J.","family":"Zielhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Boss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"10","key":"340_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et\u00a0al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883\u201392.","journal-title":"N Engl J Med"},{"issue":"7471","key":"340_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et\u00a0al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333\u20139.","journal-title":"Nature"},{"issue":"5","key":"340_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2016-0357","volume":"22","author":"M Nikanjam","year":"2017","unstructured":"Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing three-drug combinations that include targeted anti-cancer agents: analysis of 37,763 patients. Oncologist. 2017;22(5):576\u201384.","journal-title":"Oncologist"},{"issue":"3","key":"340_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41568-021-00427-0","volume":"22","author":"F Weiss","year":"2022","unstructured":"Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer. 2022;22(3):157\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"340_CR5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41598-017-01624-4","volume":"7","author":"RJ Lund","year":"2017","unstructured":"Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, Moulder R, et\u00a0al. DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer. Sci Rep. 2017;7(1):1469.","journal-title":"Sci Rep"},{"issue":"10","key":"340_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"HY Min","year":"2022","unstructured":"Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670\u201394.","journal-title":"Exp Mol Med"},{"issue":"4","key":"340_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell. 2020;37(4):471\u201384.","journal-title":"Cancer Cell"},{"issue":"1","key":"340_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-018-0775-3","volume":"17","author":"S Wu","year":"2018","unstructured":"Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17(1):25.","journal-title":"Mol Cancer"},{"key":"340_CR9","unstructured":"Bayer. Nexavar : EPAR - Product information https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexavar#product-info: European Medicines Agency 2009 [updated 18 June 2024."},{"issue":"5","key":"340_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"YJ Zhu","year":"2017","unstructured":"Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614\u201322.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"340_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","volume":"78","author":"J Ciccolini","year":"2016","unstructured":"Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78(1):1\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"340_CR12","first-page":"1707","volume":"6","author":"G Jin","year":"2013","unstructured":"Jin G, Zhao J, Qi H, Lou M, Liu X, Qu Y, et\u00a0al. Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis. Onco Targets Ther. 2013;6:1707\u201317.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"340_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00280-006-0257-y","volume":"59","author":"CA Carter","year":"2007","unstructured":"Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, et\u00a0al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol. 2007;59(2):183\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"340_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000320031","volume":"56","author":"S Ricciardi","year":"2010","unstructured":"Ricciardi S, Mey V, Nannizzi S, Pasqualetti G, Crea F, Del Tacca M, Danesi R. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy. 2010;56(4):303\u201312.","journal-title":"Chemotherapy"},{"issue":"2","key":"340_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2011.03.003","volume":"74","author":"G Pasqualetti","year":"2011","unstructured":"Pasqualetti G, Ricciardi S, Mey V, Del Tacca M, Danesi R. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer. 2011;74(2):197\u2013205.","journal-title":"Lung Cancer"},{"issue":"1","key":"340_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3892\/ol.2012.958","volume":"5","author":"J Li","year":"2013","unstructured":"Li J, Pan YY, Zhang Y. Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. Oncol Lett. 2013;5(1):68\u201372.","journal-title":"Oncol Lett"},{"issue":"1","key":"340_CR17","first-page":"346","volume":"20","author":"S Jiang","year":"2020","unstructured":"Jiang S, Wang R, Zhang X, Wu F, Li S, Yuan Y. Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non-small cell lung cancer in vitro and in vivo via the epithelial-to-mesenchymal transition process. Oncol Lett. 2020;20(1):346\u201356.","journal-title":"Oncol Lett"},{"issue":"4","key":"340_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","volume":"61","author":"CH Takimoto","year":"2008","unstructured":"Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008;61(4):535\u201348.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"340_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/COC.0b013e3181e9c0d7","volume":"34","author":"ST Tagawa","year":"2011","unstructured":"Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, et\u00a0al. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium trial NCI 6981. Am J Clin Oncol. 2011;34(5):443\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"340_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00280-011-1685-x","volume":"69","author":"B Schultheis","year":"2012","unstructured":"Schultheis B, Kummer G, Zeth M, Brendel E, Xia C, Kornacker M, Strumberg D. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2012;69(2):333\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"340_CR21","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-12-3177","volume":"19","author":"LS Schwartzberg","year":"2013","unstructured":"Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, et\u00a0al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2\u2013negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013;19(10):2745\u201354.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"340_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","volume":"12","author":"LL Siu","year":"2006","unstructured":"Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, et\u00a0al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12(1):144\u201351.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"340_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082209","volume":"9","author":"J Aparicio","year":"2014","unstructured":"Aparicio J, Garc\u00eda-Mora C, Mart\u00edn M, Petriz ML, Feliu J, S\u00e1nchez-Santos ME, et\u00a0al. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Espa\u00f1ol Multidisciplinario en C\u00e1ncer Digestivo (GEMCAD) study. PLoS ONE. 2014;9(1): e82209.","journal-title":"PLoS ONE"},{"issue":"3","key":"340_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/ajco.12191","volume":"10","author":"V Srimuninnimit","year":"2014","unstructured":"Srimuninnimit V, Sriuranpong V, Suwanvecho S. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. Asia Pac J Clin Oncol. 2014;10(3):255\u201360.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"340_CR25","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s10147-015-0796-5","volume":"20","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yue H, Xu S, Wang F, Ma N, Li K, et\u00a0al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015;20(5):952\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"340_CR26","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","volume":"28","author":"G Scagliotti","year":"2010","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et\u00a0al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(11):1835\u201342.","journal-title":"J Clin Oncol"},{"issue":"11","key":"340_CR27","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/annonc\/mds135","volume":"23","author":"A Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves A, Gilabert M, Fran\u00e7ois E, Dahan L, Perrier H, Lamy R, et\u00a0al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012;23(11):2799\u2013805.","journal-title":"Ann Oncol"},{"issue":"1","key":"340_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10637-010-9526-z","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, et\u00a0al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012;30(1):382\u20136.","journal-title":"Invest New Drugs"},{"issue":"2","key":"340_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.dld.2013.09.020","volume":"46","author":"S Cascinu","year":"2014","unstructured":"Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, et\u00a0al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase II study. Dig Liver Dis. 2014;46(2):182\u20136.","journal-title":"Dig Liver Dis"},{"issue":"25","key":"340_CR30","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","volume":"30","author":"LG Paz-Ares","year":"2012","unstructured":"Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, et\u00a0al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine\/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012;30(25):3084\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"340_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/IGC.0b013e3181e273a8","volume":"20","author":"SA Welch","year":"2010","unstructured":"Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, et\u00a0al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer. 2010;20(5):787\u201393.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"340_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bju.12437","volume":"113","author":"S Krege","year":"2014","unstructured":"Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, et\u00a0al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and\/or metastasized urothelial cancer: SUSE (AUO-AB 31\/05). BJU Int. 2014;113(3):429\u201336.","journal-title":"BJU Int"},{"issue":"6","key":"340_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.clgc.2018.07.021","volume":"16","author":"ME Hurwitz","year":"2018","unstructured":"Hurwitz ME, Markowski P, Yao X, Deshpande H, Patel J, Mortazavi A, et\u00a0al. Multicenter phase 2 trial of gemcitabine, carboplatin, and sorafenib in patients with metastatic or unresectable transitional-cell carcinoma. Clin Genitourin Cancer. 2018;16(6):437-44.e6.","journal-title":"Clin Genitourin Cancer"},{"issue":"33","key":"340_CR34","doi-asserted-by":"publisher","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","volume":"23","author":"C Sederholm","year":"2005","unstructured":"Sederholm C, Hillerdal G, Lamberg K, K\u00f6lbeck K, Dufmats M, Westberg R, Gawande SR. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23(33):8380\u20138.","journal-title":"J Clin Oncol"},{"issue":"36","key":"340_CR35","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1200\/JCO.2004.00.1438","volume":"23","author":"F Robert","year":"2005","unstructured":"Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I\/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(36):9089\u201396.","journal-title":"J Clin Oncol"},{"issue":"7","key":"340_CR36","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdl084","volume":"17","author":"RA Soo","year":"2006","unstructured":"Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, et\u00a0al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol. 2006;17(7):1128\u201333.","journal-title":"Ann Oncol"},{"issue":"5","key":"340_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3816\/CBC.2008.n.051","volume":"8","author":"DA Yardley","year":"2008","unstructured":"Yardley DA, Burris HA III, Simons L, Spigel DR, Greco FA, Barton JH, et\u00a0al. A phase II trial of gemcitabine\/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(5):425\u201331.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"340_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/1078155209105396","volume":"16","author":"CA Dasanu","year":"2010","unstructured":"Dasanu CA, Herzog TJ, Alexandrescu DT. Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration. J Oncol Pharm Pract. 2010;16(1):63\u20136.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"340_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ygyno.2011.08.018","volume":"123","author":"AN Gordon","year":"2011","unstructured":"Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, et\u00a0al. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011;123(3):479\u201385.","journal-title":"Gynecol Oncol"},{"issue":"26","key":"340_CR40","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et\u00a0al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293\u2013300.","journal-title":"J Clin Oncol"},{"issue":"4","key":"340_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/bjc.2013.432","volume":"109","author":"JK Lee","year":"2013","unstructured":"Lee JK, Capanu M, O\u2019Reilly EM, Ma J, Chou JF, Shia J, et\u00a0al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer. 2013;109(4):915\u20139.","journal-title":"Br J Cancer"},{"issue":"4","key":"340_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/bmc.2814","volume":"27","author":"NA Lankheet","year":"2013","unstructured":"Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr. 2013;27(4):466\u201376.","journal-title":"Biomed Chromatogr"},{"issue":"11","key":"340_CR43","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-07-4521","volume":"14","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, et\u00a0al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res. 2008;14(11):3477\u201386.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"340_CR44","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/bcp.13557","volume":"84","author":"EJB Derissen","year":"2018","unstructured":"Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2\u2019,2\u2019-difluorodeoxyuridine and their nucleotides. Br J Clin Pharmacol. 2018;84(6):1279\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"340_CR45","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/jms.1087","volume":"41","author":"EE Brouwers","year":"2006","unstructured":"Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom. 2006;41(9):1186\u201394.","journal-title":"J Mass Spectrom"},{"issue":"21","key":"340_CR46","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.1158\/1078-0432.CCR-05-1076","volume":"12","author":"C Ekhart","year":"2006","unstructured":"Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res. 2006;12(21):6502\u20138.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"340_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","volume":"11","author":"M Schmidinger","year":"2013","unstructured":"Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172\u201391.","journal-title":"EJC Suppl"},{"issue":"6892","key":"340_CR48","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nature00821","volume":"417","author":"HP Gerber","year":"2002","unstructured":"Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, et\u00a0al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417(6892):954\u20138.","journal-title":"Nature"},{"issue":"1","key":"340_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000493951","volume":"50","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xu L, Meng X, Qin Z, Wang Y, Chen C, et\u00a0al. Different chemotherapy regimens in the management of advanced or metastatic urothelial cancer: a Bayesian network meta-analysis of randomized controlled trials. Cell Physiol Biochem. 2018;50(1):1\u201314.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"340_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","volume":"14","author":"A Gao","year":"2023","unstructured":"Gao A, Zhang L, Zhong D. Chemotherapy-induced thrombocytopenia: literature review. Discov Oncol. 2023;14(1):10.","journal-title":"Discov Oncol"},{"issue":"5","key":"340_CR51","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ctrv.2014.02.004","volume":"40","author":"T Funakoshi","year":"2014","unstructured":"Funakoshi T, Latif A, Galsky MD. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev. 2014;40(5):636\u201347.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"340_CR52","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/jcm9103346","volume":"9","author":"R Chung","year":"2020","unstructured":"Chung R, Tyebally S, Chen D, Kapil V, Walker JM, Addison D, et\u00a0al. Hypertensive cardiotoxicity in cancer treatment-systematic analysis of adjunct, conventional chemotherapy, and novel therapies-epidemiology, incidence, and pathophysiology. J Clin Med. 2020;9(10):3346.","journal-title":"J Clin Med"},{"issue":"8","key":"340_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27679","volume":"10","author":"MJ Kang","year":"2024","unstructured":"Kang MJ, Li HX, Gan Y, Fang C, Yang XL, Li B, Su S. Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. Heliyon. 2024;10(8): e27679.","journal-title":"Heliyon"},{"issue":"6","key":"340_CR54","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10637-009-9321-x","volume":"28","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, et\u00a0al. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs. 2010;28(6):844\u201353.","journal-title":"Invest New Drugs"},{"issue":"3","key":"340_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et\u00a0al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9(3):491\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"340_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/BF00688327","volume":"37","author":"LJ van Warmerdam","year":"1996","unstructured":"van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol. 1996;37(3):266\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"340_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00044011-199815040-00009","volume":"15","author":"VR Nannan Panday","year":"1998","unstructured":"Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, et\u00a0al. Carboplatin dosage formulae can generate inaccurate predictions of carboplatin exposure in carboplatin\/paclitaxel combination regimens. Clin Drug Investig. 1998;15(4):327\u201335.","journal-title":"Clin Drug Investig"},{"key":"340_CR58","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1200\/EDBK_319783","volume":"41","author":"R Kurzrock","year":"2021","unstructured":"Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RM, Hong DS. Moving beyond 3+3: the future of clinical trial design. Am Soc Clin Oncol Educ Book. 2021;41:e133\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"340_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","volume":"34","author":"D Araujo","year":"2023","unstructured":"Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, et\u00a0al. Oncology phase I trial design and conduct: time for a change - MDICT guidelines 2022. Ann Oncol. 2023;34(1):48\u201360.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"340_CR60","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1200\/jco.2011.29.15_suppl.5019","volume":"29","author":"E Kohn","year":"2011","unstructured":"Kohn E, Lee J, Annunziata C, Minasian L, Zujewski J, Prindiville S, et\u00a0al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. J Clin Oncol. 2011;29(15_suppl):5019.","journal-title":"J Clin Oncol"},{"issue":"3","key":"340_CR61","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/sj.bjc.6605514","volume":"102","author":"JM Lee","year":"2010","unstructured":"Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, et\u00a0al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer. 2010;102(3):495\u20139.","journal-title":"Br J Cancer"},{"issue":"5","key":"340_CR62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-023-04508-9","volume":"91","author":"R Varnier","year":"2023","unstructured":"Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, et\u00a0al. Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. Cancer Chemother Pharmacol. 2023;91(5):361\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18_supply","key":"340_CR63","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1200\/jco.2007.25.18_suppl.7018","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Andreef M, Faderl S, Wright J, Zhang W, et\u00a0al. Phase I trial of intermittent administration of sorafenib (BAY 43\u20139006) for patients (pts) with refractory\/relapsed acute myelogenous leukemia (AML). J Clin Oncol. 2007;25(18_supply):7018.","journal-title":"J Clin Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00340-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00340-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00340-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:04:10Z","timestamp":1748873050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00340-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00340-8","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors declare no conflict of interest: Daphne W.M. Voogd, Merel J.J. Lucassen, Ruud van der Noll, Sybrand Zielhuis, David Boss, Jos H. Beijnen, Hilde Rosing, Matthijs Tibben, and Alwin D.R. Huitema. Neeltje Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Ellipses Pharma, GlaxoSmithKline, and Incyte; received research grants from Abbvie, Actuate Therapeutics, Amgen, Anaveon, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, CellCentric, Cogent Biosciences, Cresecendo Biologics, Deciphera, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, Janssen, Kling Biotherapeutics, Lixte, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Pfizer, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, and Zentalis. Jan H.M. Schellens is share and patent holder\u00a0of oral taxanes and CMO of Modra Pharmaceuticals and Lixte\u00a0Biotechnology. All payments were\u00a0to the Netherlands Cancer Institute and\u00a0outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice, local institutional review board ethical approval, and applicable regulatory requirements. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}